semaj83/ctmatch_classification huggingface dataset:
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly To be eligible for entry in this study, patient must Be greater than or equal to 18 years of age Have a confirmed diagnosis of acromegaly based on the following 1. Typical clinical features and 2. Mean GH concentration > 1.0 ng/mL following an oral glucose tolerance test (OGTT) and 3. Elevated serum IGF-1 levels above gender and age matched values Fall into one of the following categories: 1. Has been treated for at least the last 12 weeks with Sandostatin LAR® 10 mg or 20 mg, every 28 days with well-controlled symptoms of acromegaly and GH concentration < 2.5 ng/mL at screening or 2. Be naïve to prolonged release octreotide with a demonstrated tolerance response to a 7-day administration of Sandostatin® immediate release (50 µg s.c. t.i.d.) or 3. If previously treated with prolonged release octreotide, has stopped such treatment for at least 12 weeks prior to screening If female and of childbearing potential, must have a negative pregnancy test at screening and be using adequate means of birth control (i.e., oral or trans-dermal contraceptive drugs, intra-uterine device, diaphragm) during the study Have the ability to understand the requirements of the study, provide written informed consent to participate in this study and agree to abide by the study restrictions  To be eligible for entry in this study, patient must NOT If female, be pregnant or lactating Have been treated with a GH receptor antagonist (pegvisomant) within the last 12 weeks Have used a dopamine agonist within the last 30 days Have undergone pituitary surgery within the last 12 weeks Have undergone radiotherapy within the last two years Have any contraindication (hypersensitivity to octreotide formulation) or non-responders to Sandostatin-LAR® treatment Be currently treated with Sandostatin-LAR® and have symptoms of acromegaly that would justify, in the Investigator's opinion, a dose modification Be receiving Sandostatin-LAR® administration every < 21 or > 35 days Have a liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis, or has persistent ALT, AST > 2 X ULN, serum creatinine > 2 X ULN, serum bilirubin > 2 X ULN
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Quality of Life Acromegaly Active acromegaly Serum total IGF-I levels must have been normalized during long-term treatment with long-acting somatostatin analogs Age between 18 and 80  Any contra-indication for the use of long-acting somatostatin analogs, as e.g. the use of anti-coagulants Subjects with pituitary tumors that compress the optic chiasm Patients with insulin dependent diabetes Patients with cancer Patients with kidney or liver function disturbances Fertile female patients that refuse to take contraceptives during the study
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly Insulin Resistance Impaired Glucose Tolerance Age > 18 Diagnosed with acromegaly Safe anticonceptive for fertile women Well controlled on somatostatin analog (a serum IGF-I within normal range a nadir GH < 0.5 µg/l.)  Pregnancy Liver disease Diabetes mellitus type I Magnetic or electronic implants
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 21.0-40.0,  Polycystic Ovary Syndrome Insulin-resistant PCOS (Arm: PCOS Affected Women) Irregular menstrual cycle (Arm: PCOS Affected Women) Hyperandrogenism (Arm: PCOS Affected Women) Regular menstrual cycles (Arm: Normal Controls) Normal hormonal levels (Arm: Normal Controls) Lack of hirsutism (Arm: Normal Controls) Acne-free (Arm: Normal Controls) Candidates are BMI-matched and screened for insulin resistance prior to inclusion. (Arm: Normal Controls)  Left handedness Acute medical illness Uncorrected thyroid disease Diabetes renal Cardiac or pulmonary insufficiency Active liver disease Neurological disease Current psychiatric illness Claustrophobia Contraindications to MRI
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Polycystic Ovary Syndrome Women in reproductive age With polycystic ovary syndrome defined by hyperandrogenism (elevated serum testosterone concentrations), and oligomenorrhea (cycles of 35 days or longer), or amenorrhea (no menses in the last 6 months) after negative screening pregnancy test  Pregnancy Cushing' s syndrome Late onset congenital adrenal hyperplasia Androgen-secreting tumors Uncontrolled thyroid disease Hyperprolactinemia Diabetes any Cardiovascular diseases (Ischaemic heart disease, uncontrolled hypertension, heart failure) Acute or chronic infections at baseline Renal disease
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly The subject has given written informed consent prior to any study-related procedures The subject is male or female and is over 18 years of age The subject must have had documentation supporting the diagnosis of acromegaly, based on elevated IGF-1 and/or GH levels The subject has been receiving octreotide LAR (10 or 20 mg) treatment for at least six months and is biochemically controlled. Control is defined as normal (age and sex adjusted) IGF 1 levels for two consecutive measurements (at least two months apart) preceding study entry If the subject is receiving dopamine agonist therapy, treatment should be stable for at least four months, and no change in their dopamine-agonist medication is expected during the entire study period  The subject has received radiation therapy to the pituitary gland before study entry The subject has a history of hypersensitivity to lanreotide or drugs with a similar chemical structure The subject has received a growth hormone receptor antagonist (pegvisomant) therapy within three months before study entry The subject has undergone treatment with any other investigational drug in the 30 days before study entry or is scheduled to receive an investigational drug, other than lanreotide 120 mg, during the course of the study The subject has received any unlicensed drug within the 30 days prior to the baseline visit or is scheduled to receive an unlicensed drug during the course of the study
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Polycystic Ovary Syndrome Couples Partner with sperm concentration of >=14 million/mL in at least one ejaculate with motile sperm Ability to have regular intercourse 2-3 times per week during the ovulation induction phase of study At least one patent tube and normal uterine cavity as determined by sonohysterogram, hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years, or confirmation of a intrauterine pregnancy within the past 2 years No previous sterilization procedures(vasectomy, tubal ligation) that have been reversed Wanting to seek pregnancy Chronic anovulation or oligomenorrhea defined as intermenstrual periods of >= 45 days or a total of <=8 periods per year Hyperandrogenism will be an elevated total testosterone >=50 ng/dL Hirsutism determined by a modified Ferriman-Gallwey Score >8 PCO on ultrasound (12 or more follicles measuring 2-9 mm in diameter)  Current pregnancy Patients on oral contraceptives, depo progestins, or hormonal implants Patients with hyperprolactinemia defined as two prolactin levels at least one week apart >30 ng/mL Patients with known 21-hydroxylase deficiency by a fasting 17-hydroxyprogesterone (17-OHP) level <2 ng/mL and ACTH stimulation test as needed, or other enzyme deficiency Patients with menopausal FSH levels >20 mIU/mL Patients with uncorrected thyroid disease (TSH <0.45 mIU/ML or >4.5 mIU/ML) Patients diagnosed with Type1 or Type II diabetes Patients with liver disease defined as AST or ALT >2 times normal or total bilirubin >2.5 mg/dL Patients with renal disease defined as BUN >30 mg/dL or serum creatinine >1.4 mg/dL Patients with significant anemia (Hemoglobin <10 mg/dL)
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Acne Vulgaris Female Subjects 18-45 years of age who have achieved spontaneous menarche A clinical diagnosis of truncal acne vulgaris and the desire for an oral contraceptive for birth control A minimum of 10 but not more than 50 inflammatory lesions on the back and chest combined Maximum of 5 nodules Willing and able to understand and sign informed consent Able to complete study and comply with study procedures  Use of topical acne medications such as tretinoin, benzoyl peroxide or topical antibiotics within 2 weeks Use of oral antibiotics within 30 days Use of systemic corticosteroids within 4 weeks Use of oral contraceptives within 12 weeks Use of isotretinoin in past six months Use of phototherapy devices for acne such as ClearLight or Zenozapper within 1 week Use of tanning booths or lamps within 1 week prior to baseline BMI >30 History of renal insufficiency History of hepatic dysfunction
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 6.0-16.0,  HIV Infection Bone Mass Subject, parent, or legal guardian able and willing to provide informed consent/assent. Subject able and willing to comply with requirements of study HIV-infected subjects must have diagnosis confirmed with one or more of the following tests: 1) HIV DNA Polymerase chain reaction or HIV culture performed at any age; 2) Age >18 months, licensed ELISA with confirmatory Western Blot  Patients with history of atraumatic fractures, known renal or liver disease, known malabsorption syndrome, or inflammatory bowel disease. Use of corticosteroids, exculding inhaled steroids (current or within past 6 months) Current use of anticonvulsant drug Daily cigarette smoking Daily consumption of alcohol containing beverages Current use of tenofovir
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Psoriasis Adult with Diagnosis of chronic plaque psoriasis of the Hands and Feet for at least 6 months, with a PGA >/=3 and candidates for systemic therapy Patients in good general health Able to self-administer injections Negative chest x-ray (CXR) and purified protein derivative (PPD) test, unless willing to start anti-tuberculosis (TB) prophylaxis  Previous treatment with Required mediation stability or washouts for: systemic corticosteroids (28 days), other investigational agent, other systemic therapies for psoriasis, ultraviolet B (UVB), psoralen with UVA (PUVA) Other active skin diseases or skin infections Diagnosis of palmoplantar pustulosis; erythrodermic psoriasis, pustular psoriasis, medication-induced or exacerbated psoriasis or new onset of guttate psoriasis Evidence of dysplasia or history of malignancy (Other than a successfully treated non-metastatic cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix) History of listeriosis, histoplasmosis, chronic or active Hepatitis B infection, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active tuberculosis (TB) History of moderate to severe congestive heart failure Recent cerebrovascular accident and any other condition which, in the opinion of the investigator, would put the subject at risk History of central nervous system (CNS) demyelinating disease or neurologic symptoms suggestive of CNS demyelinating disease History of clinically significant drug or alcohol abuse in the last 12 months
Patient description: A 35-year-old woman presents with history of acne and mild hirsutism. The primary evaluation revealed elevated testosterone levels. She recently noticed gradual enlargement of her hands and feet and recognized that her ring is getting small for her finger. There is some irregularity in her menstrual cycle as well as some nipple discharge. She also has positive history for snoring and headache. The physical examination revealed subtle facial features of acromegaly and prognathism. Visual fields are normal by confrontation. Hirsutism, soft tissue thickening and diaphoresis of the hands and feet are noted. Laboratory evaluation in the fasting state reveals IGF-1 of 968 ng/mL and random GH of 19.7 ng/mL. MRI reveals a macroadenoma with no invasion. She is on stable doses of octreotide LAR since her diagnosis was confirmed. She is married and has 2 children. She is using IUD as her contraceptive method.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acromegaly Male and female patients with acromegaly Confirmed diagnosis of a growth hormone-secreting tumor Received a stable dose of monthly octreotide depot injections for a minimum of 3 consecutive months immediately prior to screening Must show a response to octreotide treatment with documented laboratory results at the screening visits defined as follows: IGF-1 < 20% above the upper limit of normal age and sex-adjusted levels and GH ≤ 2.5 ng/mL  Patients with pituitary surgery less than 3 months prior to screening Uncontrolled diabetes defined as having a fasting glucose > 150 mg/dl and HbA1c >= 9% Symptomatic cholelithiasis Received pegvisomant, Lanreotide, or a dopamine agonist within 3 months of screening, or at any time during the trial Received radiotherapy for pituitary tumor or any radiotherapy above the neck at any time before Screening